UBS O'Connor’s Theriva Biologics TOVX Stock Holding History

UBS O'Connor’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-86	Closed	-$424K	–	434
2017 Q2	$424K	Sell	86 -28	-25%	-$139K	0.01%	344
2017 Q1	$631K	Hold	114	–	–	0.01%	356
2016 Q4	$763K	Buy	+114	New	+$1.17M	0.01%	354

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

UBS O'Connor's TOVX Position: Q3 2017 in Review

UBS O'Connor sold out of Theriva Biologics (TOVX) in Q3 2017, closing a stake of 86 shares — an estimated $424K sold.

UBS O'Connor first reported a position in TOVX in Q4 2016 and held it in 3 quarters. The position peaked at $763K in Q4 2016. 51 funds tracked by Wall St. Rank hold TOVX as of Q3 2017.

UBS O'Connor reported no remaining Theriva Biologics position as of Q3 2017 after selling out during the quarter.
UBS O'Connor sold 86 Theriva Biologics shares in Q3 2017, an estimated $424K.
UBS O'Connor first reported a position in Theriva Biologics in Q4 2016 and held it in 3 quarters.
UBS O'Connor's Theriva Biologics position peaked at $763K in Q4 2016.
51 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2017.

Based on UBS O'Connor's 13F filing for Q3 2017, filed 14 Nov 2017.